First report on a prospective trial with yttrium-90–labeled ibritumomab tiuxetan (Zevalin) in primary CNS lymphoma

Most patients with primary CNS lymphoma (PCNSL) relapse after primary therapy. Standard salvage treatment has not yet been established in PCNSL. Anti-CD20 immunotherapy has expanded treatment options in systemic B-cell lymphoma; however, its use is limited by reconstitution of the blood–brain barrie...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Maza, Sofiane, Kiewe, Philipp, Munz, Dieter L., Korfel, Agnieszka, Hamm, Bernd, Jahnke, Kristoph, Thiel, Eckhard
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Duke University Press 2009
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2743222/
https://ncbi.nlm.nih.gov/pubmed/19060176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/15228517-2008-108
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller